The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non-Small Cell Lung Cancer | PTCE Pharmacy Connect

Educational Objectives Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence Faculty Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohio State University Columbus, Ohio Moderator Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Clinical Pharmacy Manager University of Kansas Cancer Center Division of Hematologic Malignancies & Cellular Therapeutics Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025. This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.